As shown in ovarian and breast cancer, tumor cell expression of VEGFR3 may generate a proliferative advantage by autocrine and paracrine signaling (Decio et al., 2014; Varney and Singh, 2015). This evidence concerns the gene FLT4 and neoplasm.